Gene and Cell Therapy for Sarcomas: A Review

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Sarcomas present treatment challenges due to heterogeneity, recurrence, and metastasis.
• Developing effective therapies for these rare cancers remains a critical need.
• Current treatment limitations necessitate exploration of novel therapeutic strategies.

Purpose of the Study:

• To comprehensively review gene and cell therapies for sarcomas.
• To analyze current literature and ongoing clinical trials in this field.
• To identify approved therapies and emerging treatment modalities.

Main Methods:

• Conducted a comprehensive literature search across PubMed, Medline, Google Scholar, and clinicaltrials.gov.
• Utilized keywords including "gene therapy," "cell therapy," "CAR-T therapy," and "sarcoma."
• Reviewed clinical trial data, noting NCT numbers, status, condition, and phase.

Main Results:

• Only three gene and cell therapies for sarcomas have received regulatory approval.
• Approved therapies include Rexin-G (2007, Philippine FDA), Gendicine (2003, China), and Afami-cel (2024, US) for synovial sarcoma.
• Numerous other promising therapies are under investigation and progressing through clinical development.

Conclusions:

• Gene and cell therapies offer significant future potential for sarcoma treatment.
• Advancements in research are moving these therapies toward late-stage clinical development.
• Integrating these novel therapies into standard care could improve patient quality of life and outcomes.